Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 107868-30-4
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Bag,Drum
Delivery Time: 7-15 days
Payment Terms: L/C, D/A, T/T, Western Union
Supply Ability: TON
CAS NO:: |
107868-30-4 |
Appearance:: |
White To Light Yellow Crystal Powder |
Molecular Formula:: |
C20H24O2 |
Molecular Weight:: |
296.40300 |
EINECS NO:: |
643-090-2 |
MDL NO:: |
MFCD00886994 |
CAS NO:: |
107868-30-4 |
Appearance:: |
White To Light Yellow Crystal Powder |
Molecular Formula:: |
C20H24O2 |
Molecular Weight:: |
296.40300 |
EINECS NO:: |
643-090-2 |
MDL NO:: |
MFCD00886994 |
Product Description:
Product Name: Exemestane CAS NO: 107868-30-4
Synonyms:
6-methylenandrost-1,4-diene-3,17-dione;
androsta-1,4-diene-6-methylene-3,17-dione;
(8R,9S,10R,13S,14S)-10,13-diMethyl-6-Methylene-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione;
Chemical & Physical Properties:
Appearance: White to light yellow crystal powder
Assay :≥99.0%
Density: 1.13 g/cm3
Boiling Point: 453.7℃ at 760 mmHg
Melting Point: 155.13℃
Flash Point: 169℃
Refractive Index: 1.572
Storage Condition: Store in original container in a cool dark place.
Vapor Pressure: 2.02E-08mmHg at 25℃
Safety Information:
HS Code: 2937900090
WGK Germany: 3
Caution Statement: P201; P305 + P351 + P338; P308 + P313
Symbol: GHS07, GHS08
Signal Word: Danger
Hazard Declaration: H319; H360
Exemestane is an irreversible steroi-d aromatase inhibitor. Its structure is similar to that of aromatase’s natural substrate, androstenedione, and acts as a pseudosubstrate. Postmenopausal women’s estrog-en is mainly converted from androg-en (produced by the adrenal cortex) by aromatase in the surrounding tissue. This drug irreversibly binds with the active site on aromatase to deactivate it, thus dramatically lower estrog-en levels in the blood circulation of postmenopausal women. By inhibiting aromatase to lower estrog-en levels, it can be used to treat hormone-dependent breast cancer in postmenopausal women.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.